Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients After Switching to Tiotropium Plus Olodaterol Fixed Dose Combination in Greece

Exclusion Criteria

• •1. Patients with contraindications according to Spiolto® Respimat® SmPC
• •2. Patients who have been treated with inhaled corticosteroids (ICS) as maintenance therapy\* or with a Long-acting beta2 adrenoceptor agonist (LABA)/Long-acting muscarinic antagonist (LAMA) combination (free or fixed dose) in the previous 6 weeks
• •\*Note: patients with temporary corticosteroids (CS) use during acute exacerbations in the previous 6 weeks can enter the study
• •3. Patients who have been treated with Spiriva® Respimat®, with other LAMA different than Spiriva®, or with a combination of Spiriva®+LABA/ICS in the previous 6 weeks
• •4. Patients diagnosed with asthma or with asthma COPD overlap syndrome (ACO)
• •5. Patients for whom availability at the enrolling site during the planned study period of approximately 3 months is not possible
• •6. Pregnancy and lactation
• •7. Patients currently listed for lung transplantation
• •8. Current participation in any clinical trial or any other non-interventional study of a drug or device.